gabapentin has been researched along with Brown Tendon Sheath Syndrome in 4 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report two cases of unusual movement disorders associated with the use of gabapentin (GBP) in patients being treated for epilepsy who were otherwise neurologically intact." | 3.69 | Movement disorders associated with the use of gabapentin. ( Krahn, LE; Reeves, AL; Sharbrough, FW; So, EL, 1996) |
| "Acquired brain injury can cause eye movement disorders which may include: strabismus, gaze deficits and nystagmus, causing visual symptoms of double, blurred or 'juddery' vision and reading difficulties." | 2.58 | Interventions for eye movement disorders due to acquired brain injury. ( Dodridge, CS; Evans, JR; Garcia-Finana, M; Hanna, K; Howard, C; Jarvis, KA; Maan, T; MacDiarmid, SL; Noonan, CP; North, L; Rodgers, H; Rowe, FJ, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rowe, FJ | 1 |
| Hanna, K | 1 |
| Evans, JR | 1 |
| Noonan, CP | 1 |
| Garcia-Finana, M | 1 |
| Dodridge, CS | 1 |
| Howard, C | 1 |
| Jarvis, KA | 1 |
| MacDiarmid, SL | 1 |
| Maan, T | 1 |
| North, L | 1 |
| Rodgers, H | 1 |
| Pistoia, F | 1 |
| Sarà, M | 1 |
| Reeves, AL | 1 |
| So, EL | 1 |
| Sharbrough, FW | 1 |
| Krahn, LE | 1 |
| Leigh, RJ | 1 |
| Ramat, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Examining the Effect of Eye Gaze Technology on Children With Cortical Visual Impairment and Its Impact on Occupational Performance[NCT06067607] | 10 participants (Anticipated) | Interventional | 2023-02-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for gabapentin and Brown Tendon Sheath Syndrome
| Article | Year |
|---|---|
Interventions for eye movement disorders due to acquired brain injury.
Topics: 4-Aminopyridine; Abducens Nerve Diseases; Amifampridine; Amines; Baclofen; Botulinum Toxins; Brain I | 2018 |
Neuropharmacologic aspects of the ocular motor system and the treatment of abnormal eye movements.
Topics: Abducens Nerve; Acetates; Amines; Baclofen; Cranial Nerve Diseases; Cyclohexanecarboxylic Acids; Eye | 1999 |
2 other studies available for gabapentin and Brown Tendon Sheath Syndrome
| Article | Year |
|---|---|
Gabapentin therapy for ocular opsoclonus-myoclonus restores eye movement communication in a patient with a locked-in syndrome.
Topics: Adult; Amines; Anticonvulsants; Cerebral Infarction; Cyclohexanecarboxylic Acids; Female; Gabapentin | 2010 |
Movement disorders associated with the use of gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Benzodiazepines; Cyclohexanecarboxylic Acids; Dyskinesia, | 1996 |